Last Price
5.68
Today's Change
-0.29 (4.85%)
Day's Change
5.61 - 6.07
Trading Volume
1,733,618
Market Cap
1 Billion
Shares Outstanding
320 Million
Avg Volume
1,962,150
Avg Price (50 Days)
7.36
Avg Price (200 Days)
5.23
PE Ratio
-35.50
EPS
-0.16
Earnings Announcement
22-Nov-2024
Previous Close
5.97
Open
6.00
Day's Range
5.61 - 6.07
Year Range
1.26 - 8.975
Trading Volume
1,733,618
1 Day Change
-4.86%
5 Day Change
-20.89%
1 Month Change
-13.41%
3 Month Change
-10.27%
6 Month Change
38.88%
Ytd Change
169.19%
1 Year Change
330.30%
3 Year Change
497.89%
5 Year Change
278.67%
10 Year Change
278.67%
Max Change
278.67%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company has collaboration with GU Research Network for an investigator initiated Trial X-Calibur, using 64Cu-SAR-bisPSMA in known or suspected prostate cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.